What is Ourobio's core technology?

Ourobio utilizes proprietary bioprocesses to convert organic industrial waste into low-footprint, bio-based chemicals and materials. Their specific proof of concept uses a single fermentation step to transform dairy waste (whey) into biodegradable plastic colorant masterbatches and polymers simultaneously, aiming to create circular and regenerative supply chains for the chemical industry.

How much funding has Ourobio raised to date?

According to slide 6, the company has secured $600,000 in total capital. This includes $400,000 in bootstrapped funds (comprising an EPA SBIR grant and various awards) and $200,000 raised from the Heritage Ventures Group and a pre-seed extension hosted on the RoundHere platform.

What stage of development is the company in?

Ourobio is at the early R&D and validation stage. Slide 5 notes they have reached Technology Readiness Level (TRL) 3/4. They have successfully produced physical samples (blue biosynthetic masterbatches) and have secured MOUs from partners, but the deck does not indicate full-scale commercial production or revenue.

Who are the founders and what is their background?

The company is led by Alec Brewer (CEO), who holds a B.S. in Biomedical Engineering and has over 5 years of entrepreneurship experience, and Kobe Rogers (COO), who holds a B.S. in Chemistry with 5 years of experience in independent biochemistry R&D. They are supported by various accelerator programs listed on slide 8.

What is missing from the Ourobio pitch deck?

The deck lacks several standard investor requirements: a specific dollar amount for the 'Ask,' detailed market sizing (TAM/SAM/SOM), a competitive landscape analysis, and five-year financial projections. It also omits unit economics, which are critical for assessing the viability of waste-to-value biotechnology models.

Ourobio Pitch Deck (2022): 10-Slide Pre-Seed Deck

See all 10 slides of the Ourobio pitch deck — a 2022 deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

Ourobio presents a concise 10-slide deck focused on their proprietary bioprocesses that convert organic industrial waste into low-footprint chemicals and materials. The company has reached Technology Readiness Level (TRL) 3/4, successfully producing polymers and colorants from whey using engineered strains. With $400k in bootstrapped funding and $200k raised from Heritage Ventures Group and RoundHere, the team is seeking pre-seed and seed introductions to scale their vision. While the deck effectively communicates their technical proof of concept and early traction, it lacks critical financia…

Key takeaways

The company has achieved TRL 3/4, producing polymers and colorants from whey with an engineered strain (Slide 5).
Ourobio has secured $400k in bootstrapped funding, including an EPA SBIR grant and competition awards (Slide 6).
A total of $200k has been raised from Heritage Ventures Group and through a pre-seed extension on RoundHere (Slide 6).
The proof of concept involves a single fermentation step to produce complementary bio-based plastic additives simultaneously (Slide 4).
Market discovery efforts exceeded 1000 hours and resulted in MOUs from both upstream and downstream partners (Slide 5).
The innovation roadmap targets a portfolio of PHA co-polymers and multi-colored masterbatches beyond the initial blue colorant (Slide 7).
The deck omits standard financial metrics, including market size, unit economics, and a specific capital requirement for the current round (Slides 9-10).
The team consists of two co-founders with backgrounds in Chemistry and Biomedical Engineering, supported by a wide array of accelerators like Halcyon and MassChallenge (Slide 8).

Ourobio Pitch Deck Analysis

Ourobio is positioning itself as a key player in the circular bioeconomy, specifically targeting the chemicals and materials industry. This 10-slide deck serves as a high-level introduction to their technology and early-stage traction. It focuses heavily on the 'why' and the 'how' of their bioprocess, while leaving much of the 'how much' (financials and market size) to follow-up conversations.

Slide 1: Title Slide

The deck opens with a clean logo and the tagline: "Catalyzing the circular bioeconomy." The branding is professional and thematic, using blues and greens to signal environmental sustainability. There is no mention of the specific round or date on this slide, though the source listing indicates a late 2022 timeframe.

Slide 2: The Thesis

Slide 2 presents a simple, bold statement: "Biotechnology is the sustainable alternative to petrochemistry." This serves as the foundational belief of the company. It is a high-level industry observation rather than a specific problem statement, which is a common approach in deep-tech decks where the 'problem' (petrochemical pollution) is widely acknowledged by the target investor audience.

Slide 3: The Vision and Tech Overview

Ourobio defines its role as the "chemical and materials industry’s bioeconomy partner." The slide explains that they use industrial byproducts to produce low-footprint, targeted additives. A three-part graphic illustrates the flow: Organic waste from industry goes into Ourobio’s proprietary bioprocesses, resulting in low-footprint, bio-based chemicals and materials. This slide successfully communicates the circularity of their business model.

Slide 4: Our First Product

This is the 'Proof of Concept' slide. Ourobio specifies that their first application turns "dairy waste into low-footprint biodegradable plastic colorant masterbatches." The technical highlight here is the "single fermentation step" used to produce complementary bio-based additives simultaneously. The slide includes a visual of the "Blue Biosynthetic Masterbatches," providing a tangible output for an otherwise abstract biological process.

Slide 5: Traction and Achievements

Slide 5 provides concrete evidence of progress. Key metrics include:

TRL 3/4: Bootstrapped R&D has reached the stage of producing polymers and colorants from whey using an engineered strain. · 1000+ hours of market discovery: This effort yielded MOUs from both upstream and downstream partners, indicating market pull. · IP Status: The technology is patent-pending with a defined patent family and follow-on strategy.

The slide also features a quote from StartUs Insights naming them one of the "5 Top Biomaterials Startups You Should Watch in 2022."

Slide 6: Additional Milestones

This slide details the company's capitalization and operational history:

$400k bootstrapped: This includes an EPA SBIR (Small Business Innovation Research) grant and various competition awards. · $200k raised: Sourced from Heritage Ventures Group and a pre-seed extension on RoundHere. · 15+ successful intern & consulting engagements: Demonstrating organizational growth. · 3+ year-long relationships: Established with VCs and prospective partners.

The mention of the EPA SBIR is a significant validator for a biotech startup, as these grants involve rigorous technical peer review.

Slide 7: Innovation Roadmap

Ourobio outlines its future pipeline, moving from the initial Blue Masterbatches into:

Biodegradable Plastic Blends · Portfolio of PHA co-polymers · Multi-colored Masterbatches · Novel, performance-enhancing additives

This slide is intended to show that Ourobio is a platform company, not just a 'blue dye' company. However, it lacks a timeline or specific milestones for these developments.

Slide 8: The Team

Kobe Rogers (COO): B.S. Chemistry, with 5 years of independent biochemistry R&D experience. · Alec Brewer (CEO): B.S. BME (Biomedical Engineering), with 5+ years of entrepreneurship and small business experience.

The right side of the slide is crowded with logos from accelerators and partners, including Halcyon, Virginia Tech, GC3, D3, EPA, VentureWell, Plug and Play, and MassChallenge. While the logos provide social proof, the slide lacks a deep bench of senior advisors or industry veterans, which is often expected in complex biotech ventures.

Slide 9: The Ask

Pre-seed/Seed Investor Intros · Organic Waste Streams · Corporate Champion(s)

Crucially, it does not state how much money they are currently raising, the valuation, or the specific use of funds. In a formal pitch deck, investors typically expect a clear dollar amount and a breakdown of how that capital will move the company to the next TRL or commercial milestone.

Slide 10: Contact Slide

The deck concludes with contact information for both founders. The design remains consistent with the rest of the deck, maintaining the professional aesthetic.

What Ourobio Does Well

Technical Clarity: The deck does an excellent job of explaining a complex biological process in simple terms. The use of dairy waste (whey) as a specific feedstock makes the abstract concept of 'organic waste' much more relatable and understandable for a generalist investor.

Validation: Mentioning the EPA SBIR grant and the TRL 3/4 status provides necessary technical credibility. The claim of 1000+ hours of market discovery shows that the founders are not just building in a lab but are actively talking to the market.

Visual Storytelling: The graphics on slides 3, 4, and 7 effectively communicate the circular nature of the business and the potential for a broad product platform.

What is Missing from the Deck

Market Sizing: There is no mention of the Total Addressable Market (TAM). Investors need to know if the plastic colorant market or the PHA polymer market is large enough to support a venture-scale return.

Financial Projections: The deck contains no forward-looking financials. There is no indication of when the company expects to reach revenue, what their margins look like, or the cost-competitiveness of their bio-based masterbatches compared to traditional petrochemical alternatives.

Competitive Landscape: Ourobio does not address who else is working in the waste-to-polymer space. A competitive matrix or a 'Why Us' slide comparing their single-step fermentation to multi-step processes would have strengthened the case for their proprietary advantage.

Specific Funding Ask: As noted, slide 9 is too generic. A founder should always specify the amount they are raising and what milestones that money will buy (e.g., "Raising $1.5M to build a pilot plant and achieve TRL 6").

Founder Takeaways

Focus on the 'Platform': Ourobio successfully frames their first product as a proof of concept for a larger platform. Founders of deep-tech companies should follow this lead: show one specific, viable application to prove the tech works, then show the roadmap for how that tech scales into other verticals.

Leverage Non-Dilutive Funding: Highlighting the $400k in bootstrapped/grant funding is a strong signal. It shows that the founders are resourceful and that external government bodies (EPA) have vetted the technology.

Don't Hide the Numbers: While this deck works as a 'teaser,' a full investor deck must include market size and a clear financial ask. If you are asking for 'intros,' you are networking; if you are asking for 'capital,' you need to name the price and the plan.

Frequently asked questions

What is Ourobio's core technology?: Ourobio utilizes proprietary bioprocesses to convert organic industrial waste into low-footprint, bio-based chemicals and materials. Their specific proof of concept uses a single fermentation step to transform dairy waste (whey) into biodegradable plastic colorant masterbatches and polymers simultaneously, aiming to create circular and regenerative supply chains for the chemical industry.
How much funding has Ourobio raised to date?: According to slide 6, the company has secured $600,000 in total capital. This includes $400,000 in bootstrapped funds (comprising an EPA SBIR grant and various awards) and $200,000 raised from the Heritage Ventures Group and a pre-seed extension hosted on the RoundHere platform.
What stage of development is the company in?: Ourobio is at the early R&D and validation stage. Slide 5 notes they have reached Technology Readiness Level (TRL) 3/4. They have successfully produced physical samples (blue biosynthetic masterbatches) and have secured MOUs from partners, but the deck does not indicate full-scale commercial production or revenue.
Who are the founders and what is their background?: The company is led by Alec Brewer (CEO), who holds a B.S. in Biomedical Engineering and has over 5 years of entrepreneurship experience, and Kobe Rogers (COO), who holds a B.S. in Chemistry with 5 years of experience in independent biochemistry R&D. They are supported by various accelerator programs listed on slide 8.
What is missing from the Ourobio pitch deck?: The deck lacks several standard investor requirements: a specific dollar amount for the 'Ask,' detailed market sizing (TAM/SAM/SOM), a competitive landscape analysis, and five-year financial projections. It also omits unit economics, which are critical for assessing the viability of waste-to-value biotechnology models.

Cover slide of the Ourobio pitch deck — Pre-seed / Seed 2022 — Ourobio pitch deck, slide 1 (2022)

Ourobio pitch deck: the facts

Company: Ourobio
Year: 2022
Stage: Pre-seed / Seed
Slides: 10
Sector: Biotechnology / Circular Economy
Deck type: Investor Pitch Deck
Headquarters: United States (implied by Virginia Tech / EPA / UVA logos)

Ourobio pitch deck PDF

The full Ourobio deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Ourobio pitch deck was used for

This is Ourobio’s updated pitch deck from December 2022, a roughly 10‑slide pre‑seed/seed‑stage fundraising deck aimed at investors in biotechnology and circular economy solutions. The company positions itself as a synthetic biology and biomaterials startup using industrial and agricultural byproducts—initially dairy waste—to produce biodegradable plastic resins and colorant masterbatches. At the time of this deck, they highlight a proof‑of‑concept fermentation process that co‑produces bio‑based biodegradable plastic and pigments from whey-containing byproducts. The deck appears designed to support an early equity round following 2022 grants and accelerator participation, and around the time of a reported pre‑seed raise.

Business model: Develops engineered microorganisms and proprietary fermentation/bioprocesses that convert food and agricultural processing byproducts (especially whey-containing dairy byproducts) into low-footprint, bio-based biodegradable plastic resins and additives (including colorants/pigments), selling into chemicals, materials and consumer goods supply chains.

Year: 2022
Headquarters: Indianapolis, Indiana, United States.

Round: Pre-seed, with other sources broadly describing early-stage/seed activity in 2022.

Raised: A data provider reports a pre-seed round of approximately $150,000 completed in August 2022.

Industry: Biotechnology; Synthetic biology; Biomaterials; Circular economy; Chemicals and materials additives.

What happened after the Ourobio deck

Following the 2022 updated pitch deck, Ourobio advanced its proof-of-concept technology for co-producing biodegradable plastic resins and colorants from whey byproducts, secured at least one SBIR grant and accelerator support, and reportedly raised an early pre-seed round. Subsequent listings on investment and data platforms indicate continued fundraising activity and development of its circular b

Demonstrated proof of concept co-production of biodegradable plastic resins (e.g., PHB/PHAs) and pigments from whey-cont
Participated in accelerator/incubator programs (including Lighthouse Labs Spring 2022) and obtained multiple grants and
Reportedly closed a pre-seed round of approximately $150,000 in August 2022, contemporaneous with the updated deck.
By 2025, appeared on an investment platform raising additional capital for circular biomanufacturing tech, with disclose

What the Ourobio deck got right

Differentiated single-fermentation co-production of resins and pigments. Ourobio’s technology is positioned as uniquely able to co-produce biodegradable plastic resins and pigments from whey-containing dairy byproducts in a single-step fermentation, potentially reducing energy and water usage compared with conventional masterbatch preparation and lowering cost and footprint.
Strong circular economy and sustainability positioning. The deck and surrounding materials clearly tie the platform to dairy waste and agricultural byproducts, offering a circular supply-chain solution that helps food and ag processors manage residues while enabling brands to produce fully bio-based, biodegradable products and packaging.
Defined B2B customer focus in plastics and packaging. Ourobio targets business development, procurement, and sustainability leaders at plastic converters and consumer brands, indicating a B2B go-to-market approach that integrates into existing materials supply chains rather than requiring end-consumer behavior change.
Mix of grant, accelerator, and early equity validation. The company’s early trajectory combines accelerator participation, grants (including an SBIR award), and a reported pre-seed equity round, signaling external validation and some funding diversity even at a very early stage.
Potentially scalable manufacturer/licensor business model. Later descriptions show flexibility in business model—operating as both a manufacturer and licensor of its fermentation technology—which may support capital-efficient scaling through partners alongside in-house production.
Consistent alignment with ESG and regulatory trends. Messaging across the deck and external profiles consistently emphasizes low-footprint, bio-based, biodegradable materials, aligning the narrative with regulatory trends and corporate ESG/circularity goals in packaging and consumer goods.

What could have been stronger

Limited clearly documented unit economics and scale metrics in early materials. Public materials around the time of the 2022 deck emphasize proof-of-concept co-production of biodegradable plastic and colorants from whey, but provide limited, clearly sourced quantitative data on unit economics (cost per kilogram, margin vs. conventional masterbatch) or commercial-scale production metrics, which can make it harder for investors to model the business.
Early commercial traction not concretely quantified. The deck and surrounding descriptions focus on the technical novelty of co-producing resins and pigments from agricultural byproducts but give less detail on specific customer contracts, pilots, or revenue figures, leaving early commercial traction largely unquantified in public information from that period.
Limited third-party validation highlighted alongside the deck. While the technology is described as unique in its ability to convert whey byproducts into non-toxic colored biodegradable plastic in a single-step fermentation, investors may find relatively few third-party validations or industrial partner case studies cited alongside the deck to corroborate performance at scale.
Fragmented public view of financing history. Multiple sources mention grants, accelerator funding, a pre-seed round, and planned seed rounds, but they present incomplete and sometimes inconsistent snapshots of the company’s financing history, which can complicate an investor’s understanding of capitalization and runway if not clarified in the deck or conversation.
Regulatory and certification strategy not deeply elaborated. Regulatory, safety, and certification pathways for new bio-based pigments and polymers are not extensively detailed in publicly accessible pitch materials from 2022, yet these factors can significantly affect time-to-market and adoption in packaging and consumer goods.

How an investor would read this deck

What draws attention

Technical novelty of single-fermentation co-production of biodegradable plastic resins (e.g., PHB/PHAs) and pigments from whey-containing dairy byproducts, which could lower costs and environmental impact versus conventional plastics and masterbatch production.
Clear alignment with circular economy and sustainability mandates by converting industrial food and agricultural byproducts into higher-value materials for packaging and consumer products.
Combination of revenue potential from materials supply with non-dilutive grants and accelerator support, suggesting some validation and funding leverage in early stages.
Positioning as both manufacturer and licensor (in later materials), which may offer flexible business model pathways and scalability if the technology can be deployed through partners.

Risks that stand out

Scale-up risk in moving from proof-of-concept and grant-funded R&D to reliable commercial-scale fermentation and downstream processing, given the technical complexity of co-producing and co-extracting resins and pigments from whey.
Market adoption risk if plastic converters and brands face barriers integrating new biodegradable resins and colorants into existing formulations, processing equipment, or certification regimes.
Financing risk, as publicly visible information shows modest pre-seed and grant funding amounts with incomplete disclosure of later equity rounds, suggesting potential need for substantial additional capital to fund scale-up facilities.
Competitive risk from other biomaterials and bioplastics companies, including those focusing on PHAs or bio-based pigments, which may already have downstream partnerships or scale advantages.
Feedstock and supply-chain risk, as dependence on food and ag processing byproducts like whey requires robust partnerships and logistics to ensure consistent quality and volume at industrial scale.

Questions this deck invites

What are the current and projected unit economics for Ourobio’s biodegradable plastic resins and additives compared with conventional petrochemical masterbatch and bioplastic alternatives (cost, margin, scalability)?
Which specific commercial customers (plastic converters, brands) are under contract or in pilots, and what volume commitments or revenue have been generated since the 2022 proof of concept?
What is the current technology readiness level: demonstration scale, pilot production, or commercial manufacturing, and what capex is required to reach meaningful production volumes?
How does Ourobio’s intellectual property position look (patents, licenses, know-how), and are there any freedom-to-operate concerns around PHAs, pigments, or fermentation processes?
What regulatory, safety, and certification steps (e.g., for food-contact packaging, environmental claims) are necessary for these bio-based pigments and polymers, and how far along is Ourobio in those pathways?

What founders can take from the Ourobio deck

A clearly articulated proof of concept that ties a specific waste stream (whey-containing dairy byproducts) to a tangible product (biodegradable plastic resins and colorant masterbatches) can make an early-stage synthetic biology story more concrete to investors.
Positioning technology within broader circular economy and sustainability narratives, such as lowering cost and footprint for bio-based packaging, can align the deck with regulatory and corporate ESG trends that investors track.
Combining discussion of grants, accelerator participation, and early pre-seed equity in the fundraising narrative highlights non-dilutive validation and can help show momentum even before large commercial contracts are signed.
Explaining how engineered microorganisms co-produce complementary biomaterials in a single fermentation (resins and pigments) demonstrates both scientific differentiation and potential economic advantages, which can be compelling in technical slides.
Clarifying target customers (plastic converters and brands, and their procurement/sustainability functions) helps investors see the route to market for a platform biomaterials technology rather than viewing it as purely research-focused.
Maintaining consistency and transparency about fundraising history (grants, accelerators, pre-seed, seed attempts) is important, as fragmented public data can create questions that the deck should proactively address.

Ourobio pitch deck: common questions

What does Ourobio do?

Ourobio is an early-stage synthetic biology and biomaterials company that develops engineered microorganisms and proprietary fermentation processes to turn industrial food and agricultural byproducts into low-footprint biodegradable plastic resins and additives, including colorants. Their initial proof of concept uses whey-containing dairy processing byproducts to co-produce biodegradable plastic resins and pigments in a single fermentation.

Which industry and customers is Ourobio targeting?

Public information indicates that Ourobio operates in the biotechnology, synthetic biology, biomaterials, chemicals, and circular economy sectors, focusing on supplying biodegradable plastic resins and additives to chemicals, materials, plastic converters, and consumer brands. Their customers are described as business development, procurement, and sustainability leads at plastic converters and brands who mix Ourobio’s colored concentrates into larger batches of biopolymer resin.

Has Ourobio raised funding, and was this deck tied to a specific round?

A data provider reports that Ourobio raised a pre-seed round of approximately $150,000 in August 2022. Other sources list multiple grants, accelerator/Incubator funding, and seed round entries around 2022, but specific investors and final equity round details are not clearly disclosed. As of the 2022 deck, the company appears to have been using the pitch to support this early pre-seed/seed fundraising alongside non-dilutive grant and accelerator funding.

How does Ourobio’s technology work at a high level?

Ourobio’s proof of concept technology uses engineered microbes to convert dairy processing byproducts containing whey into bio-based biodegradable plastic resins (such as PHB/PHAs) and indigoid pigments simultaneously in a single-step fermentation. This co-production approach is intended to reduce energy and water usage compared with conventional masterbatch preparation and to lower the cost and footprint of fully bio-based, brandable biodegradable products and packaging.

What happened after the 2022 Ourobio deck—did the company progress?

The December 2022 updated deck presents Ourobio as an early-stage pre-seed/seed biotech startup with a proof of concept for converting dairy waste into biodegradable plastic colorant masterbatches. Subsequent information shows that by late 2022 they had secured at least one SBIR grant and accelerator support, and by 2025 they were listed on an investment platform raising additional capital for their circular biomanufacturing technology. Details on later commercial traction or completed larger equity rounds remain limited in public sources.

Sources

Funding and outcome facts on this page were researched on 2026-08-22 from the pages below.

Ourobio pitch deck slides

Ourobio pitch deck slide 1 of 10 — Ourobio pitch deck — slide 1 of 10

Ourobio pitch deck slide 2 of 10 — Ourobio pitch deck — slide 2 of 10

Ourobio pitch deck slide 3 of 10 — Ourobio pitch deck — slide 3 of 10

Ourobio pitch deck slide 4 of 10 — Ourobio pitch deck — slide 4 of 10

Ourobio pitch deck slide 5 of 10 — Ourobio pitch deck — slide 5 of 10

Ourobio pitch deck slide 6 of 10 — Ourobio pitch deck — slide 6 of 10

What each slide of the Ourobio pitch deck says

Slide 2

Biotechnology is the sustainable alternative to petrochemistry. QUDbio

Slide 3

Tech We want to be the chemical and materials industry’s rq Orgerc waste " rom inaustry bioeconomy partner. |) Our unique biotechnology uses industrial <8 — ) byproducts to produce low-footprint, PLN proprietary targeted additives for the chemicals & =r : bioprecesses materials industry. hal ) Our bioprocesses help create supply JA Low-footprint, bio-based chains that are circular and regenerative. Ct ghemiegsSmatenals I QU Dvio

Slide 4

Our first product 2 (% Organic Our proof of concept turns Mie gus ol | . i I By-products dairy waste into low-footprint biodegradable plastic colorant | masterbatches. Fo le Our proprietary bioprocess uses a opie single fermentation step to produce pilin ze complementary bio-based, biodegradable plastic additives | simultaneously. 4 Blue Biosynthetic Fr Masterbatches = OJDbio

Slide 5

Traction and achievements We have made significant progress since pivoting last year. ® id) s i Bootstrapped R&D to 1000+ hours of Patent pending TRL 3/4 - producing market discovery technology with polymers & colorant yielded MOUs patent family & from whey with our from up and down follow-on IP engineered strain. stream partners. strategy. StartUsul “One of the 5 Top Biomaterials =="insights STARTUPS YOU SHOULD WATCH IN 2022." a QUDbio

Slide 6

Additional milestones we’ve got many other accomplishments that show for it too. $400k bootstrapped, including EPA SBIR and a number of competitions/awards $200k raised from the Heritage Ventures Group and on RoundHere (where we are hosting our F&F / pre-seed extension) 15+ successful intern & consulting engagements 3+ year-long relationships with VCs and prospective partners See LinkedIn and RoundHere for more! = OJDbio

Slide text above is read directly from the Ourobio deck PDF embedded on this page.